论文部分内容阅读
目的探讨孕足月胎膜早破孕妇静脉滴注缩宫素引产的临床疗效。方法选取2013年5月至2014年5月在确诊为孕足月超过38周且胎膜早破的286例孕妇,将其采用随机数字表法分为两组。对照组患者采用林格液且当宫口开至3 cm后停止使用缩宫素;而观察组从患者感觉宫缩至分娩结束持续使用缩宫素。比较两组孕妇的分娩方式、新生儿情况以及产后情况。结果观察组孕妇的剖宫产率、产褥感染率,胎儿窘迫率、新生儿高胆红素血症率均明显低于对照组,缩宫素使用时间明显高于对照组,差异均有统计学意义(均P<0.05)。结论胎膜早破的孕妇应用缩宫素至分娩结束可提高母婴的安全性,降低产妇以及新生儿的并发症发生率。
Objective To investigate the clinical efficacy of intravenous infusion of oxytocin in pregnant women with premature rupture of membranes during pregnancy. Methods From May 2013 to May 2014, 286 pregnant women who had been diagnosed as full-term pregnancy for more than 38 weeks and premature rupture of membranes were selected and divided into two groups by random number table. Patients in the control group were treated with Ringer’s solution and stopped using oxytocin when the cervix was opened to 3 cm. Patients in the observation group continued to use oxytocin from the time the patient felt uterine contractions to the end of delivery. The mode of delivery, newborns and postpartum were compared between the two groups. Results The cesarean section rate, puerperal infection rate, fetal distress rate and neonatal hyperbilirubinemia rate in the observation group were significantly lower than those in the control group, and the use time of oxytocin was significantly higher than that of the control group Significance (both P <0.05). Conclusion The application of oxytocin to pregnant women with premature rupture of membranes may increase the safety of maternal and infant and reduce the incidence of complications of maternal and newborn babies.